Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis

Trial Profile

Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor (Primary) ; Clopidogrel
  • Indications Cardiovascular disorders; Thrombosis
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 03 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 03 Aug 2015 Planned primary completion date changed frm 1 May 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
    • 15 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top